09.04.24
Olon, a chemical-pharmaceutical group, has announced plans to acquire HuvePharma Italia Srl and its site in Garessio, (Cuneo, Italy).
The acquisition plan involves a complete operational integration of Huvepharma Italia Srl and a plan to revive the production potential of the Garessio plant and, through the development of new business opportunities, bring it to full production capacity. With this latest acquisition, the Group now totals nine manufacturing plants in Italy and a total reaction capacity of 3,250 cubic meters.
Huvepharma Italia Srl, with its plant in Garessio, operates in the development, industrialization, production via chemical synthesis, and marketing of active ingredients for pharmaceutical use, as well as advanced intermediates.
The company is a well-established player in the pharmaceutical chemicals market with extensive experience in the development and production of APIs, and in tracking the introduction and adoption of new technologies.
This transaction aims to strengthen and broaden Olon’s product offering with a focus on the most strategic areas. The acquisition of Huvepharma Italia constitutes a significant step forward in terms of capacity growth. The plan envisages the integration and valorization in its entirety of all assets: facilities, workforce, and product portfolio.
“We recognized in Huvepharma Italia all the right characteristics,” commented Paolo Tubertini, CEO of Olon Group. “The acquisition supports the implementation of the Group's medium to long term strategy and the achievement of our business objectives. We will capitalize on the integration with Olon's existing manufacturing network, which already includes 12 sites worldwide and 7 integrated and interconnected research centers, with our consolidated customer portfolio, which includes all the major pharmaceutical companies in the market, and our solid reputation as a partner and API supplier. The objective of the transaction is to significantly increase our overall API production capacity by unlocking the potential of the Garessio site.”
The transaction will take place through the purchase of the company, with full ownership transferred to Olon and complete integration within the Group. The company's assets, facility and staff will be included and integrated.
The acquisition plan involves a complete operational integration of Huvepharma Italia Srl and a plan to revive the production potential of the Garessio plant and, through the development of new business opportunities, bring it to full production capacity. With this latest acquisition, the Group now totals nine manufacturing plants in Italy and a total reaction capacity of 3,250 cubic meters.
Huvepharma Italia Srl, with its plant in Garessio, operates in the development, industrialization, production via chemical synthesis, and marketing of active ingredients for pharmaceutical use, as well as advanced intermediates.
The company is a well-established player in the pharmaceutical chemicals market with extensive experience in the development and production of APIs, and in tracking the introduction and adoption of new technologies.
Olon’s Expansion Strategy
Since its inception, the Olon Group has pursued a strategy of growth, consolidation and expansion on the global market, both internally and externally, through acquisitions.This transaction aims to strengthen and broaden Olon’s product offering with a focus on the most strategic areas. The acquisition of Huvepharma Italia constitutes a significant step forward in terms of capacity growth. The plan envisages the integration and valorization in its entirety of all assets: facilities, workforce, and product portfolio.
“We recognized in Huvepharma Italia all the right characteristics,” commented Paolo Tubertini, CEO of Olon Group. “The acquisition supports the implementation of the Group's medium to long term strategy and the achievement of our business objectives. We will capitalize on the integration with Olon's existing manufacturing network, which already includes 12 sites worldwide and 7 integrated and interconnected research centers, with our consolidated customer portfolio, which includes all the major pharmaceutical companies in the market, and our solid reputation as a partner and API supplier. The objective of the transaction is to significantly increase our overall API production capacity by unlocking the potential of the Garessio site.”
The transaction will take place through the purchase of the company, with full ownership transferred to Olon and complete integration within the Group. The company's assets, facility and staff will be included and integrated.
